Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Amvis Holdings.Inc. ( (JP:7071) ).
Amvis Holdings has approved the issuance of paid stock acquisition rights as stock options to its directors and employees, aiming to boost motivation, align interests with shareholders, and support medium- to long-term growth in its comprehensive medical support business. The Sixth Series options will go to CEO Keiichi Shibahara, with exercise tied to performance and share price targets, plus a mandatory exercise clause if the share price falls below 50% of the exercise price to ensure shared downside risk and discourage actions that could depress the stock.
The Seventh Series options will be allotted to directors and employees, including 10,000 rights for Director Kosuke Saita, and are similarly linked to performance and share price goals but without a mandatory exercise condition. If fully exercised, the options would dilute existing shareholders by 2.55% of current shares, which the company views as a reasonable impact given the expected enhancement of corporate and shareholder value through greater equity ownership by management.
The most recent analyst rating on (JP:7071) stock is a Hold with a Yen491.00 price target. To see the full list of analyst forecasts on Amvis Holdings.Inc. stock, see the JP:7071 Stock Forecast page.
More about Amvis Holdings.Inc.
Amvis Holdings, Inc. is a Tokyo-based healthcare company focused on comprehensive medical support services. Listed on the Tokyo Stock Exchange Prime, it operates through a group structure and is positioning its comprehensive medical support business as a key medium- to long-term growth driver.
Average Trading Volume: 681,344
Technical Sentiment Signal: Sell
Current Market Cap: Yen49.06B
For a thorough assessment of 7071 stock, go to TipRanks’ Stock Analysis page.